Who we are
Set up in the final days of Nicki’s life by her closest family, including her son and daughter, The Nicki Waterman Foundation is dedicated to supporting the research of Dr Paul Mulholland, the neuro-oncologist who treated Nicki.
The Nicki Waterman Foundation is a small, family run enterprise where all monies raised go directly into research, and no donations are used to facilitate the running and administration of the organisation.
“I cannot bring my mummy back but I can make sure to do my best to keep her name and legacy going. I want to ensure that more research is done into finding a cure for this horrendous disease.”
– Nicki’s daughter, Alex
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive form cancer that begins in the brain. Its initial symptoms are usually non-specific, starting with headaches, nausea and, as in Nicki’s case, sometimes presenting as symptoms similar to stroke.
At the moment the median survival time for patients with glioblastoma is 15 to 16 months for those who have surgery, chemotherapy, and radiation treatment.
While Nicki’s tumour was inoperable, her life was prolonged by a pioneering immunotherapy treatment called called ipilimumab, which was only available to her through private medical insurance.
This treatment gave Nicki an extra 15 months of life, during which time she was able to see her son get married and spend time with her daughter and precious grandchildren.
About Dr Paul Mulholland
At the moment, brain tumours kill more children and adults under the age of 40 than any other cancer, but just 1% of the national spend on cancer research has been allocated to them.
However, further treatment to improve the outcomes of glioblastoma patients is being developed by Nicki’s own neuro-oncologist Dr Paul Mulholland.
Dr Paul Mulholland is a medical oncologist who exclusively treats brain cancer. He is a consultant at University College Hospital, the National Hospital for Neurology and Neurosurgery and Mount Vernon Cancer Centre, and he is chair of the HCA Cancer Care brain and CNS tumour board.
Dr Mulholland is also an honorary senior lecturer at University College London and a training programme director. Today his main research is in understanding the immune microenvironment of glioblastoma and using this to improve the effectiveness and outcomes of immunotherapeutic treatments like Nicki’s.
The research group lead by Dr Paul Mulholland aims to improve patient outcomes for those with glioblastoma. The clinical practice is based at University College London Hospitals and the National Hospital for Neurology & Neurosurgery, where Nicki was treated.